The current BBB pattern-of-complaints alert flags unfilled medications and slow support, with no clinic response to BBBs outreach as of the alert posting
As you can see from the side-by-side Figure below, the new trial (at left) replicates the previous one for symptomatic benefit and reduced physical limitations (Y-axis, corresponding to the Kansas City score) with the primary endpoint findings remarkably similar
Generic Price Collapse Before August 2023, Vyvanse had no generic competition
Iversen, Vegard M., et al
Among those who have used GLP-1 drugs, about half report they have experienced nausea and about one-third experienced diarrhea
Ozempic and Wegovy have both benefited from expanded regulatory indications, resulting in larger patient pool eligibility (diabetes, obesity, cardiovascular, and kidney protection)